ACLY and cancer: For example, the ACLY inhibitor bempedoic acid (ETC-1002) was already authorized by the U.S. Food and Drug Administration (FDA) in 2020 as a non-statin LDL-C lowering drug for atherosclerotic cardiovascular disease, as well as being used in cancer treatment therapeutics [110, 111].